A5034366220- Pulmonary Hypertension Research and Treatments
- Heart Failure Treatment and Management
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Vascular Anomalies and Treatments
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Mental Health and Psychiatry
- Hormonal and reproductive studies
- Sexual function and dysfunction studies
- Neurology and Historical Studies
- Cardiovascular and exercise physiology
- Cardiovascular Issues in Pregnancy
- Liver Disease Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Pharmacological Effects and Toxicity Studies
- Liver Disease and Transplantation
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Management and Research
- Epilepsy research and treatment
- Chronic Myeloid Leukemia Treatments
- Renin-Angiotensin System Studies
- Historical Psychiatry and Medical Practices
- Adolescent and Pediatric Healthcare
- Blood Pressure and Hypertension Studies
- Pharmaceutical Economics and Policy
- Atomic and Subatomic Physics Research
Io Therapeutics (United States)
2024
Bellerophon Therapeutics (United States)
2019-2020
Gilead Sciences (United States)
2011-2017
Life Pacific College
2017
PAREXEL International (United Kingdom)
2016
CACI International (United Kingdom)
2015
University of Chicago
2012
Pfizer (United Kingdom)
2005-2010
St Thomas' Hospital
2005
Pfizer (United States)
2002
Data on the effect of initial combination therapy with ambrisentan and tadalafil long-term outcomes in patients pulmonary arterial hypertension are scarce.In this event-driven, double-blind study, we randomly assigned, a 2:1:1 ratio, participants World Health Organization functional class II or III symptoms who had not previously received treatment to receive 10 mg plus 40 (combination-therapy group), placebo (ambrisentan-monotherapy (tadalafil-monotherapy all administered once daily. The...
<h3>Background</h3> Patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an attenuated response compared idiopathic PAH most trials. Thus, there is uncertainty regarding the benefit of PAH-targeted therapy some forms CTD-PAH. <h3>Objective</h3> To explore safety and efficacy initial combination ambrisentan tadalafil versus or monotherapy patients CTD-PAH SSc-PAH enrolled AMBITION trial. <h3>Methods</h3> This...
The clinical course of pulmonary hypertension (PH) in idiopathic fibrosis (IPF) is not known except advanced disease.488 subjects a placebo-controlled study ambrisentan IPF with mild-moderate restriction lung volume, underwent right heart catheterisation (RHC) at baseline and 117 (24%) had repeated haemodynamic measurements 48 weeks. were categorised into a) World Health Organization (WHO) Group 3 PH (PH associated disease), n=68 (14%); b) WHO 2 left-sided cardiac n=25 (5%); c) no but...
Between 1953 and 1974 the author made psychiatric examinations for prosecution of 400 persons, 367 males 33 females, accused murders 307 victims, 194 113 females. The were 273 murders, 172 male 101 female females 34 22 13 victims. salient features amongst maleness, youthfulness, causal importance alcohol, rarity suicide after murder an high percentage psychiatrically normal persons: in these last two respects picture differed from that reported England Wales. normality Scottish was further...
It has been increasingly the practice in Scotland for Procurators-Fiscal to obtain psychiatric opinions on mental state of all persons accused murder. Between 1953 and 1964 I made 66 such examinations, mainly Glasgow area; because other commitments none were carried out between July 1955 March 1958. The official Criminal Statistics England Wales (1) show that during eleven years from 1963 number found guilty murder was 395 manslaughter 969; comparable figures (3) 43 148.
Section:ChooseTop of pageAbstract <<Inadequacies Therapy o...Why a Precision Medicine ...PVDOMICS, Linking Phenoty...The Role Large Data An...Considerations in the Con...Considerations Des...The ChallengesSummary Recommendation...ReferencesCITING ARTICLES
Background Inhibition of the transporter-mediated hepatobiliary elimination bile salts is a putative mechanism for liver toxicity observed with some endothelin receptor antagonists (ERAs). Methods Sandwich-cultured human hepatocytes were used to study distribution and accumulation exogenous taurocholate, ERAs endogenous acids. The molecular mechanisms findings in or clinical observations further explored using either vesicular assays (efflux transporters) transfected cell-lines (uptake...
To assess pharmacokinetics and pharmacodynamics of a 10 mg intravenous sildenafil bolus in pulmonary arterial hypertension (PAH) patients stabilized on 20 orally three times daily.Pharmacokinetic parameters were calculated using noncompartmental analysis.After an acute increase, plasma concentrations within the range reported previously for oral tablet. At 0.5 h, mean ± SD changes from baseline -8.4 11.7 mmHg (systolic pressure), -2.6 7.3 (diastolic pressure) -3.5 10.4 beats min(-1) (heart...
Gillies, Hunter, Wayne E. Derman, Timothy D. Noakes, Peter Smith, Alicia Evans, and Gary Gabriels.Pseudoephedrine is without ergogenic effects during prolonged exercise. J. Appl. Physiol. 81(6): 2611–2617, 1996.—This study was designed to measure whether a single dose of 120 mg pseudoephedrine ingested min before exercise influences performance 1 h high-intensity The on urinary excretion the drug were also studied. Ten healthy male cyclists tested two occasions, separated by at least 7 days,...
ObjectivePulmonary arterial hypertension (PAH) is a condition which may lead to right ventricular failure and early mortality an important complication in patients with connective tissue disease (CTD). Previously, the endothelin A selective receptor antagonist, ambrisentan, demonstrated efficacy safety treating PAH due WHO Group I etiologies. These analyses describe 3-year of ambrisentan specifically CTD associated (CTD-PAH).MethodsPatients CTD-PAH participating ARIES-1 -2 clinical trials...
Pulmonary arterial hypertension (PAH) causes right ventricular ischemia, dysfunction, and failure. PAH patients may benefit from antianginal agents based on a shared pathophysiology with left ischemia. A single-center, randomized, placebo-controlled trial (1∶1) to assess the acute vasoreactivity safety of ranolazine in was conducted. Plasma samples for pharmacokinetic (PK) studies were drawn during hemodynamic measurements at 0, 60, 90, 120, 240, 360 minutes Swan-Ganz catheter. All received...
Abstract AV‐101 (imatinib) powder for inhalation, an investigational dry inhaled formulation of imatinib designed to target the underlying pathobiology pulmonary arterial hypertension, was generally well tolerated in healthy adults a phase 1 single and multiple ascending dose study. I nhaled m atinib P ulmonary A rterial H ypertension C linical T rial (IMPAHCT; NCT05036135) is 2b/3, randomized, double‐blind, placebo‐controlled, dose‐ranging, confirmatory IMPAHCT identify optimal (phase 2b...
Background Oral imatinib has been shown to be effective, but poorly tolerated, in patients with advanced pulmonary arterial hypertension (PAH). To maintain efficacy while improving tolerability, AV-101, a dry powder inhaled formulation of imatinib, was developed deliver directly the lungs. Methods This phase 1, placebo-controlled, randomised single ascending dose (SAD) and multiple (MAD) study evaluated safety/tolerability pharmacokinetics AV-101 healthy adults. The SAD included five cohorts...
Abstract Aim To provide estimates of the costs severe and non‐severe insulin‐related hypoglycaemia in UK using Local Impact Hypoglycaemia Tool. Methods Rates were extracted from Study Group observational study. The hypoglycaemic episodes insulin‐treated adults with Type 1 2 diabetes estimated data sources. rates then applied to specific populations give an estimate cost for , a locality, or user‐defined population. User‐specific could also be applied. Results episode can range as much £2,152...
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex multi-symptom disease with widespread evidence of disrupted systems. The authors hypothesize that it caused by the upregulation corticotropin-releasing factor receptor type 2 (CRFR2) in raphé nuclei and limbic system, which impairs ability to maintain homeostasis. propose utilizing agonist-mediated endocytosis downregulate CRFR2.This open-label trial tested safety, tolerability efficacy an acute dose CT38s (a...